MA33920B1 - Modulateurs allosteriques positifs du recepteur m1 a base de quinolinamide - Google Patents

Modulateurs allosteriques positifs du recepteur m1 a base de quinolinamide

Info

Publication number
MA33920B1
MA33920B1 MA35061A MA35061A MA33920B1 MA 33920 B1 MA33920 B1 MA 33920B1 MA 35061 A MA35061 A MA 35061A MA 35061 A MA35061 A MA 35061A MA 33920 B1 MA33920 B1 MA 33920B1
Authority
MA
Morocco
Prior art keywords
quinolinamide
positive allosteric
allosteric modulators
receptor
receptor based
Prior art date
Application number
MA35061A
Other languages
Arabic (ar)
English (en)
Inventor
Scott D Kuduk
Kelly-Ann Schlegel
Zhi-Qiang Yang
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA33920B1 publication Critical patent/MA33920B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C07D215/60—N-oxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La présente invention concerne des composés de quinolinamide de formule (i) qui constituent des modulateurs allostériques positifs du récepteur m1 et qui peuvent être utilisés dans le cadre du traitement de maladies dans lesquelles est impliqué le récepteur m1, comme la maladie d'alzheimer, la schizophrénie, la douleur ou les troubles du sommeil. L'invention concerne également des compositions pharmaceutiques contenant lesdits composés et l'utilisation desdits composés et compositions dans le cadre du traitement de maladies à médiation par le récepteur m1.
MA35061A 2009-12-17 2010-12-13 Modulateurs allosteriques positifs du recepteur m1 a base de quinolinamide MA33920B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28753509P 2009-12-17 2009-12-17
PCT/US2010/060007 WO2011084368A1 (fr) 2009-12-17 2010-12-13 Modulateurs allostériques positifs du récepteur m1 à base de quinolinamide

Publications (1)

Publication Number Publication Date
MA33920B1 true MA33920B1 (fr) 2013-01-02

Family

ID=44305688

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35061A MA33920B1 (fr) 2009-12-17 2010-12-13 Modulateurs allosteriques positifs du recepteur m1 a base de quinolinamide

Country Status (41)

Country Link
US (2) US9199939B2 (fr)
EP (1) EP2512243B1 (fr)
JP (1) JP5651708B2 (fr)
KR (1) KR101494059B1 (fr)
CN (1) CN102651970B (fr)
AR (1) AR079510A1 (fr)
AU (1) AU2010340142B2 (fr)
BR (1) BR112012014180A2 (fr)
CA (1) CA2782347C (fr)
CL (1) CL2012001605A1 (fr)
CO (1) CO6551729A2 (fr)
CR (1) CR20120327A (fr)
CY (1) CY1117726T1 (fr)
DK (1) DK2512243T3 (fr)
DO (1) DOP2012000167A (fr)
EA (1) EA022494B1 (fr)
EC (1) ECSP12011983A (fr)
ES (1) ES2575154T3 (fr)
GE (1) GEP201606506B (fr)
GT (1) GT201200201A (fr)
HN (1) HN2012001265A (fr)
HR (1) HRP20160574T1 (fr)
HU (1) HUE029734T2 (fr)
IL (1) IL220130A0 (fr)
MA (1) MA33920B1 (fr)
ME (1) ME02421B (fr)
MX (1) MX336774B (fr)
NI (1) NI201200107A (fr)
NZ (1) NZ600674A (fr)
PE (1) PE20121613A1 (fr)
PH (1) PH12012501222A1 (fr)
PL (1) PL2512243T3 (fr)
PT (1) PT2512243E (fr)
RS (1) RS54798B1 (fr)
SG (1) SG181719A1 (fr)
SI (1) SI2512243T1 (fr)
TN (1) TN2012000231A1 (fr)
TW (1) TWI412525B (fr)
UA (1) UA106406C2 (fr)
WO (1) WO2011084368A1 (fr)
ZA (1) ZA201204313B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
CA2789331C (fr) * 2010-02-11 2017-11-07 Northwestern University Modulateurs des recepteurs nmda a structure secondaire stabilisee et leurs utilisations
KR20180101641A (ko) 2010-05-17 2018-09-12 포럼 파마슈티칼즈 인크. (R)-7-클로로-N-(퀴누클리딘-3-일)벤조[b]티오펜-2-카르복사미드 히드로클로리드 모노히드레이트의 결정질 형태
US8815902B2 (en) 2010-06-15 2014-08-26 Merck Sharp & Dohme Corp. Tetrahydroquinoline amide M1 receptor positive allosteric modulators
EP2709621B1 (fr) * 2011-05-17 2016-11-02 Merck Sharp & Dohme Corp. Modulateurs allostériques positifs du récepteur m1 au quinoline-amide à liaison n
EP2821401B1 (fr) 2012-03-02 2020-09-09 Takeda Pharmaceutical Company Limited Composés de dihydroquinolinone en tant que modulateurs du récepteur muscarinique m1
EP3461481A1 (fr) 2012-05-08 2019-04-03 Forum Pharmaceuticals Inc. Procédés de maintien, de traitement ou d'amélioration de la fonction cognitive
EP2921480B1 (fr) 2012-11-19 2017-10-11 Takeda Pharmaceutical Company Limited Composé hétérocyclique contenant de l'azote
TW201512197A (zh) * 2013-08-30 2015-04-01 Hoffmann La Roche 吡咯并吡啶或吡唑并吡啶衍生物
MX2016001942A (es) * 2013-09-27 2016-06-02 Hoffmann La Roche Derivados de indol e indazol.
GB201317363D0 (en) * 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
WO2015110370A1 (fr) * 2014-01-22 2015-07-30 F. Hoffmann-La Roche Ag Dérivés de fluoro-naphtyle
WO2015190564A1 (fr) * 2014-06-13 2015-12-17 武田薬品工業株式会社 Composé hétérocyclique contenant de l'azote
WO2016009297A1 (fr) 2014-07-18 2016-01-21 Pfizer Inc. Dérivés de la pyridine en tant que modulateurs allostériques positifs du récepteur m1 muscarinique
WO2016198342A1 (fr) 2015-06-09 2016-12-15 Bayer Pharma Aktiengesellschaft Modulateurs positivement allostériques du récepteur muscarinique m2
EP3347349B1 (fr) * 2015-09-10 2019-09-18 Suven Life Sciences Limited Dérivés de fluoroindole en tant que modulateurs allostériques positifs du récepteur muscarinique m1
WO2017099969A1 (fr) * 2015-12-10 2017-06-15 Merck Sharp & Dohme Corp. Modulateurs allostériques positifs du récepteur muscarinique m1 tétrahydroquinoxaline
EP3416639B1 (fr) * 2016-02-16 2022-06-08 Vanderbilt University Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m1
WO2017151449A1 (fr) * 2016-03-04 2017-09-08 Merck Sharp & Dohme Corp. Composés modulateurs allostériques positifs du récepteur m1 et leurs méthodes d'utilisation
CA3030204A1 (fr) 2016-07-11 2018-01-18 Bayer Pharma Aktiengesellschaft Amides de l'acide 1-pyridyl-naphthyridin-3-carboxylique substitues en position 7, et leur utilisation
SMT202000554T1 (it) 2016-09-02 2020-11-10 Suven Life Sciences Ltd Modulatori allosterici positivi del recettore muscarinico m1
JOP20190045A1 (ar) 2016-09-14 2019-03-14 Bayer Ag مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها.
US10899759B2 (en) 2016-09-30 2021-01-26 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor M1
EA035599B1 (ru) * 2017-04-13 2020-07-14 Сувен Лайф Сайенсиз Лимитед Позитивные аллостерические модуляторы мускариновых m1-рецепторов
PT3643718T (pt) 2017-06-20 2023-10-26 Takeda Pharmaceuticals Co Composto heterocíclico e seu uso como modulador alostérico positivo do recetor muscarínico colinérgico m1
AU2018289939B2 (en) * 2017-06-20 2022-06-16 Takeda Pharmaceutical Company Limited Heterocyclic compound
NZ763341A (en) * 2017-10-27 2023-03-31 Suven Life Sciences Ltd Polycyclic amides as muscarinic m1 receptor positive allosteric modulators
US11970483B2 (en) 2018-09-28 2024-04-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
US12162864B2 (en) 2018-09-28 2024-12-10 Takeda Pharmaceutical Company Limited Condensed-cyclic compound
MX2021004471A (es) 2018-10-17 2021-08-24 Suven Life Sciences Ltd Derivados de pirrolo-pididazina como moduladores alostéricos positivos del receptor muscarínico m1.
WO2020086864A1 (fr) 2018-10-24 2020-04-30 Vanderbilt University Modulateurs allostériques positifs du récepteur d'acétylcholine muscarinique m1
US20250064833A1 (en) 2021-12-13 2025-02-27 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
KR20030027094A (ko) 2000-08-29 2003-04-03 야마노우치세이야쿠 가부시키가이샤 신규 에스테르 또는 아미드 유도체
EP1596867A4 (fr) 2003-02-19 2006-03-22 Merck & Co Inc Traitement de la psychose avec un activateur ectopique du récepteur m1 muscarinique
EP1601357A4 (fr) * 2003-03-10 2007-10-03 Schering Corp Inhibiteurs de kinase heterocycliques : procedes d'utilisation et de synthese
SE0302139D0 (sv) * 2003-07-28 2003-07-28 Astrazeneca Ab Novel compounds
DK1701951T3 (da) 2003-12-23 2010-06-07 Serodus As Modulatorer af perifere 5-HT receptorer
WO2005094834A1 (fr) * 2004-03-17 2005-10-13 Glaxo Group Limited Antagonistes du recepteur d'acetylcholine muscarinique
WO2007100366A2 (fr) * 2005-12-05 2007-09-07 Merck & Co., Inc. Modulateurs allostériques positifs du récepteur de la quinolone m1
CN101321733A (zh) * 2005-12-05 2008-12-10 默克公司 喹诺酮m1受体阳性变构调节剂
PE20091036A1 (es) 2007-11-30 2009-08-15 Astrazeneca Ab Derivado de quinolina como antagonista del receptor p2x7
CA2716921A1 (fr) * 2008-03-21 2009-09-24 Merck Sharp & Dohme Corp. Modulateurs allosteriques positifs du recepteur m1 de la quinolizidine
PE20120031A1 (es) 2008-11-20 2012-02-05 Merck Sharp & Dohme Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1
JP2012518640A (ja) 2009-02-23 2012-08-16 メルク・シャープ・エンド・ドーム・コーポレイション ピラゾロ［４，３−ｃ］シンノリン−３−オンＭ１受容体陽性アロステリックモジュレーター
WO2010123716A1 (fr) 2009-04-20 2010-10-28 Merck Sharp & Dohme Corp. Modulateurs allostériques positifs d'un récepteur m1 de cinnoline fusionnée hétérocyclique
MY160075A (en) 2009-08-31 2017-02-15 Merck Sharp & Dohme Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
WO2011049731A1 (fr) 2009-10-21 2011-04-28 Merck Sharp & Dohme Corp. Composés de quinoléinone-pyrazolone modulateurs allostériques positifs du récepteur m1
US8754220B2 (en) 2009-11-20 2014-06-17 Merck Sharp & Dohme Corp. Quinolizidinone carboxamide M1 receptor positive allosteric modulators
EP2512245B1 (fr) 2009-12-14 2014-07-23 Merck Sharp & Dohme Corp. Modulateurs allostériques positifs des récepteurs m1 de pyridoquinazolinone
US8383638B2 (en) 2009-12-21 2013-02-26 Merck Sharp & Dohme Aminobenzoquinazolinone M1 receptor positive allosteric modulators
WO2011149801A1 (fr) 2010-05-28 2011-12-01 Merck Sharp & Dohme Corp. Composés de naphthalène carboxamide, modulateurs allostériques positifs du récepteur m1
US8815902B2 (en) 2010-06-15 2014-08-26 Merck Sharp & Dohme Corp. Tetrahydroquinoline amide M1 receptor positive allosteric modulators
WO2011159553A1 (fr) 2010-06-15 2011-12-22 Merck Sharp & Dohme Corp. Compposés de phénanthrolinone fusionnés hétérocycliques utiles comme modulateurs allostériques positifs du récepteur m1
EP2709621B1 (fr) 2011-05-17 2016-11-02 Merck Sharp & Dohme Corp. Modulateurs allostériques positifs du récepteur m1 au quinoline-amide à liaison n

Also Published As

Publication number Publication date
KR20120084324A (ko) 2012-07-27
EP2512243B1 (fr) 2016-04-06
RS54798B1 (sr) 2016-10-31
ME02421B (fr) 2016-09-20
WO2011084368A1 (fr) 2011-07-14
HK1170122A1 (zh) 2013-02-22
NI201200107A (es) 2012-10-30
CN102651970A (zh) 2012-08-29
CO6551729A2 (es) 2012-10-31
US20160075656A1 (en) 2016-03-17
ES2575154T3 (es) 2016-06-24
MX2012007013A (es) 2012-07-03
TWI412525B (zh) 2013-10-21
SI2512243T1 (sl) 2016-07-29
TW201130824A (en) 2011-09-16
PE20121613A1 (es) 2012-12-02
GEP201606506B (en) 2016-07-11
EA201290519A1 (ru) 2013-01-30
HUE029734T2 (en) 2017-03-28
CN102651970B (zh) 2014-11-12
AU2010340142B2 (en) 2014-05-08
PL2512243T3 (pl) 2016-09-30
AU2010340142A1 (en) 2012-06-14
ZA201204313B (en) 2016-01-27
MX336774B (es) 2016-01-28
NZ600674A (en) 2013-05-31
CL2012001605A1 (es) 2012-10-05
ECSP12011983A (es) 2012-07-31
HN2012001265A (es) 2015-09-07
IL220130A0 (en) 2012-07-31
AR079510A1 (es) 2012-02-01
CA2782347A1 (fr) 2011-07-14
PH12012501222A1 (en) 2012-11-05
JP2013514358A (ja) 2013-04-25
US9199939B2 (en) 2015-12-01
HRP20160574T1 (hr) 2016-06-17
EP2512243A1 (fr) 2012-10-24
GT201200201A (es) 2015-05-20
UA106406C2 (ru) 2014-08-26
BR112012014180A2 (pt) 2015-09-15
CA2782347C (fr) 2014-09-23
SG181719A1 (en) 2012-07-30
EA022494B1 (ru) 2016-01-29
DK2512243T3 (en) 2016-07-25
EP2512243A4 (fr) 2013-05-29
JP5651708B2 (ja) 2015-01-14
PT2512243E (pt) 2016-06-08
DOP2012000167A (es) 2012-12-31
TN2012000231A1 (en) 2013-12-12
CR20120327A (es) 2012-07-30
CY1117726T1 (el) 2017-05-17
US20120252808A1 (en) 2012-10-04
KR101494059B1 (ko) 2015-02-16

Similar Documents

Publication Publication Date Title
MA33920B1 (fr) Modulateurs allosteriques positifs du recepteur m1 a base de quinolinamide
MA31845B1 (fr) Pipéridino-dihydrothiénopyrimidines substituées
EP2037739A4 (fr) Effecteurs allostériques positifs du récepteur m1 à base de quinolone à substitution benzyle
TN2010000230A1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
MA32798B1 (fr) Acides naphtylacétiques
MA33239B1 (fr) 3h-imidazo [4,5-c] pyridine-6-carboxamides en tant qu'anti-inflammatoires
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
ATE475650T1 (de) Positive allosterische chinolon-m1- rezeptormodulatoren
MA34650B1 (fr) Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane
MA31373B1 (fr) Composes amino-heterocycliques
MA33467B1 (fr) Promédicaments comprenant un conjugué insuline-lieur
EA201170705A1 (ru) Арилметилбензохиназолиноны в качестве позитивных аллостерических модуляторов рецептора м1
MA35576B1 (fr) Nouveaux composés
MA33053B1 (fr) Inhibiteurs de la poly(adp-ribose) polymerase (parp)
MA30999B1 (fr) Composés.
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
EP1673078A4 (fr) Inhibiteurs de type benzylether et benzylamino de beta-secretase pour le traitement de la maladie d'alzheimer
MA32804B1 (fr) Antagonistes d'isonicotinamide des récepteurs de l'orexine
MA30041B1 (fr) Immunoglobulines
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
EP2091328A4 (fr) Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer
MA29169B1 (fr) Formulations intraveineuses d'inhibiteurs de la pde-5
MA29723B1 (fr) Composes
MA37763A1 (fr) Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu'inhibiteurs de bace1
MA37691B1 (fr) 5-amino[1,4]thiazines comme inhibiteurs de bace1